Brirnonidine tartrate 0.1% eyedrops new and effective treatment of rosacea

ABSTRACT

To determine the efficacy of brimonidine tartrate eye drops for treatment of erythema associated with rosacea. Fifty patients with rosacea [41 females and 9 males, mean age 35 years] were randomized to receive once daily single application of BT or vehicle for 4 weeks. Evaluation at 8 weeks included clinician's erythema assessment [CEA], patient's self-assessments [PSA] and photographic documentation. Based on CEA and PSA, clinical response of 96.5% was seen with BT eyedrops as compared to 20.8% with placebo [p<0.05]. Increased burning sensation and dermatitis was seen with BT in 2 [8.7%] patients, while rebound erythema occurred in 1 [4.3%] after BT use. Single daily application of BT eye drops provides significantly greater efficacy than vehicle for treatment of moderate to severe erythema of rosacea